PolyMedix Obtains US Patent For Angiogenesis Inhibitor Compounds

The US Patent and Trademark Office has issued a patent to PolyMedix, relating its angiogenesis inhibitors.

The patent number 7,553,876, entitled ‘Polycationic Compounds and Uses Thereof,’ relates to therapeutic uses of PolyMedix compounds for inhibiting angiogenesis.

Angiogenesis is a process involving the growth of new blood vessels. Lucentis and Macugen are two products currently approved for treatment of age-related macular degeneration (AMD). PolyMedix’s angiogenesis inhibitors may have a mechanism of action distinct from compounds that only inhibit VEGF (vascular endothelial growth factor).

Nicholas Landekic, president and chief executive officer, PolyMedix, said: “This is an exciting accomplishment for PolyMedix. This patent represents the first allowance from our applications relating to angiogenesis inhibition, and another compelling example of the efficiency and capabilities of our drug discovery approach.”